Plain-English translation of NCT06037902 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a device called CPAP (Continuous Positive Airway Pressure) — which gently pushes air into your lungs to keep them expanded — can help protect your healthy lung and heart tissue during radiation therapy for esophageal cancer. Researchers want to see if using this breathing device during your radiation planning scans can reduce how much radiation reaches these vital organs. You would undergo two planning scans: one with the device and one without, so doctors can compare the results.
When radiation therapy is used to treat esophageal cancer, it can sometimes damage healthy tissues like the lungs and heart that are near the tumor. This trial exists to find out whether this breathing device can help position your organs in a way that keeps them safer from radiation during treatment.
You likely qualify if…
You likely don't qualify if…
Your participation involves undergoing two radiation planning simulation sessions (called CT scans) — one where you'll use the breathing device and one where you won't. This allows your doctors to compare how the device affects radiation exposure to your lungs and heart. The study doesn't change your actual radiation treatment plan; it's purely to gather information that may help guide future patient care. Your regular radiation therapy would continue as planned by your medical team.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
Israel
Sponsor
Sheba Medical Center
Enrollment target
~44 participants
Started
August 2023
Primary completion
September 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2023.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.